The CD34⁺ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors

Authors

M. Remberger^{1, 4}, B. Grønvold¹, M. Ali¹, J. Mattsson⁵, T. Egeland², K. U. Lundin², A. Myhre¹, I. Abrahamsen^1, , D. Heldal¹, I. Dybedal¹, G. E. Tjønnfjord^{1, 3}, T. Gedde-Dahl^{1, 3}, Y. Fløisand^{1, 6, *}

¹Department of Hematology, Oslo University Hospital, Oslo, Norway

²Department of Immunology, Oslo University Hospital, Oslo, Norway

³Institute of Clinical Medicine, University of Oslo, Oslo, Norway

⁴Department of Medical Sciences, Uppsala University and KFUE, Uppsala University Hospital, Uppsala, Sweden

⁵Hans Messner Allogeneic Transplant Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada

⁶Centre for Cancer Cell Reprogramming, Department of Molecular Cell Biology, Oslo University Hospital, Montebello, N-0379 Oslo, Norway

^*Corresponding author. Tel.: +47 23070460. Email: yfloisan@ous-hf.no

DOI

10.2991/chi.d.200221.001How to use a DOI?

Keywords

Cell dose; CD34; HSCT; GVHD; PBSC

Abstract

The effect of CD34⁺ cell dose in allogeneic hematopoietic stem cell transplantation (HSCT) on overall survival (OS) and incidence of acute and chronic graft-versus-host disease (GvHD) has not been established and few studies have been performed. Our single center analysis included 189 patients with hematological malignancies who received peripheral blood stem cell (PBSC) grafts from sibling donors. Myeloablative conditioning was used in 88 cases and 101 received reduced intensity conditioning. The median CD34⁺ cell dose was 5.6 × 10⁶/kg (0.6–17.0). In the multivariate analysis, a CD34 cell dose of 6–7 × 10⁶/kg was associated with better OS and lower transplant-related mortality (TRM), while a dose of <5 × 10⁶/kg led to increased relapse and reduced chronic GVHD (cGVHD). A high CD34 cell-dose (>6.5 × 10⁶/kg) correlated with less acute GVHD (aGVHD) II–IV. We conclude that the CD34 cell dose has an impact on the outcome of HSCT from sibling donor PBSCs.

Copyright

© 2020 International Academy for Clinical Hematology. Publishing services by Atlantis Press International B.V.

Open Access

This is an open access article distributed under the CC BY-NC 4.0 license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)
View full text (HTML)

TY  - JOUR
AU  - M. Remberger
AU  - B. Grønvold
AU  - M. Ali
AU  - J. Mattsson
AU  - T. Egeland
AU  - K. U. Lundin
AU  - A. Myhre
AU  - I. Abrahamsen
AU  - D. Heldal
AU  - I. Dybedal
AU  - G. E. Tjønnfjord
AU  - T. Gedde-Dahl
AU  - Y. Fløisand
PY  - 2020
DA  - 2020/03/04
TI  - The CD34+ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors
JO  - Clinical Hematology International
SP  - 74
EP  - 81
VL  - 2
IS  - 2
SN  - 2590-0048
UR  - https://doi.org/10.2991/chi.d.200221.001
DO  - 10.2991/chi.d.200221.001
ID  - Remberger2020
ER  -